Patents Assigned to INNOPHARMAX INC.
-
Publication number: 20220233649Abstract: The disclosure relates to a dosage forms and combinations of dosage forms useful for effective oral administration of drugs which are otherwise unsuitable for oral administration, owing to acid- and/or protease-mediated degradation. The dosage forms include a self-microemulsifying drug delivery system (SMEDDS) with which the drug is combined and an antacid. When co-administered to a mammal, the dosage form(s) can prevent drug degradation by the strong acid and digestive enzymes normally present in the gastric environment, and can improve water-soluble drug absorption in gastrointestinal (GI) tract. The dosage forms can be used to effectively administer insulin by an oral route, for example, such as in the form of a powder that can be stored for long periods and reconstituted with water or another fluid shortly before administration.Type: ApplicationFiled: April 13, 2022Publication date: July 28, 2022Applicant: InnoPharmax, Inc.Inventors: Yu-Tsai YANG, Jong-Jing WANG, Pei-Jing HSU, Li-Chien CHANG, Wei-Hua HAO, Chang-Shan HSU
-
Patent number: 11331376Abstract: The disclosure relates to a dosage forms and combinations of dosage forms useful for effective oral administration of drugs which are otherwise unsuitable for oral administration, owing to acid- and/or protease-mediated degradation. The dosage forms include a self-microemulsifying drug delivery system (SMEDDS) with which the drug is combined and an antacid. When co-administered to a mammal, the dosage form(s) can prevent drug degradation by the strong acid and digestive enzymes normally present in the gastric environment, and can improve water-soluble drug absorption in gastrointestinal (GI) tract. The dosage forms can be used to effectively administer insulin by an oral route, for example, such as in the form of a powder that can be stored for long periods and reconstituted with water or another fluid shortly before administration.Type: GrantFiled: November 4, 2015Date of Patent: May 17, 2022Assignee: INNOPHARMAX, INC.Inventors: Yu-Tsai Yang, Jong-Jing Wang, Pei-Jing Hsu, Li-Chien Chang, Wei-Hua Hao, Chang-Shan Hsu
-
Patent number: 10835548Abstract: The disclosure relates to compositions and methods for treatment, such as inducing regression or inhibiting growth, of tumors in a patient such as a human. Use of gemcitabine, including in self-emulsifying orally administered dosage forms for these purposes is described. Gemcitabine is orally administered in a metronomic manner, which involves repeatedly administering a therapeutic amount of gemcitabine, being a fraction of the maximum tolerated dose, over an extended period of time, preferably on a non-interrupted schedule of weeks, months, or indefinitely.Type: GrantFiled: June 2, 2017Date of Patent: November 17, 2020Assignee: INNOPHARMAX, INC.Inventors: Wei-Hua Hao, Shu-Ping Hsueh, Chang-Shan Hsu
-
Publication number: 20190275006Abstract: The present invention provides an oral self micro-emulsifying pharmaceutical composition of a hydrophilic drug or a pharmaceutically acceptable salt thereof which, in addition to the hydrophilic drug, one or more solvents for solving the hydrophilic drug to form a drug-solvent solution and a surfactant system, further comprises one or more hydrophilic carrier which are compatible with said drug-solvent solution and the surfactant system. The oral self micro-emulsifying pharmaceutical composition of the invention exhibits comparative bioavailability to that of the hydrophilic drug through injection and is stable during storage. A method for preparing the oral self micro-emulsifying pharmaceutical composition is also provided.Type: ApplicationFiled: May 23, 2019Publication date: September 12, 2019Applicant: INNOPHARMAX, INC.Inventors: Chang-Shan HSU, Wei-Hua HAO, Jong-Jing WANG, Tsung-Hsin LIN
-
Publication number: 20170360894Abstract: The disclosure relates to a dosage forms and combinations of dosage forms useful for effective oral administration of drugs which are otherwise unsuitable for oral administration, owing to acid- and/or protease-mediated degradation. The dosage forms include a self-microemulsifying drug delivery system (SMEDDS) with which the drug is combined and an antacid. When co-administered to a mammal, the dosage form(s) can prevent drug degradation by the strong acid and digestive enzymes normally present in the gastric environment, and can improve water-soluble drug absorption in gastrointestinal (GI) tract. The dosage forms can be used to effectively administer insulin by an oral route, for example, such as in the form of a powder that can be stored for long periods and reconstituted with water or another fluid shortly before administration.Type: ApplicationFiled: November 4, 2015Publication date: December 21, 2017Applicant: InnoPharmax, Inc.Inventors: Yu-Tsai YANG, Jong-Jing WANG, Pei-Jing HSU, Li-Chien CHANG, Wei-Hua HAO, Chang-Shan HSU
-
Publication number: 20170348341Abstract: The disclosure relates to compositions and methods for treatment, such as inducing regression or inhibiting growth, of tumors in a patient such as a human. Use of gemcitabine, including in self-emulsifying orally administered dosage forms for these purposes is described. Gemcitabine is orally administered in a metronomic manner, which involves repeatedly administering a therapeutic amount of gemcitabine, being a fraction of the maximum tolerated dose, over an extended period of time, preferably on a non-interrupted schedule of weeks, months, or indefinitely.Type: ApplicationFiled: June 2, 2017Publication date: December 7, 2017Applicant: InnoPharmax, Inc.Inventors: Wei-Hua HAO, Shu-Ping Hsueh, Chang-Shan Hsu
-
Patent number: 9750702Abstract: A pharmaceutical composition used to treat Parkinson's disease contains levodopa, carbidopa and entacapone or pharmaceutically acceptable salt thereof, and at least one kind of pharmaceutically acceptable excipients. Entacapone is not mixed with levodopa or carbidopa in the pharmaceutical composition. The preparation method of the pharmaceutical composition includes making the first particles with levodopa and carbidopa, making the second particles with entacapone, and then pressing the two kinds of particles into tablets.Type: GrantFiled: December 25, 2009Date of Patent: September 5, 2017Assignee: INNOPHARMAX, INC.Inventors: Weihua Hao, Jongjing Wang, Huiyun Chen
-
Publication number: 20150196537Abstract: The present invention provides an oral self micro-emulsifying pharmaceutical composition of a hydrophilic drug or a pharmaceutically acceptable salt thereof which, in addition to the hydrophilic drug, one or more solvents for solving the hydrophilic drug to form a drug-solvent solution and a surfactant system, further comprises one or more hydrophilic carrier which are compatible with said drug-solvent solution and the surfactant system. The oral self micro-emulsifying pharmaceutical composition of the invention exhibits comparative bioavailability to that of the hydrophilic drug through injection and is stable during storage. A method for preparing the oral self micro-emulsifying pharmaceutical composition is also provided.Type: ApplicationFiled: March 26, 2015Publication date: July 16, 2015Applicant: Innopharmax, Inc.Inventors: Chang-Shan HSU, Wei-Hua HAO, Jong-Jing WANG, Tsung-Hsin LIN
-
Patent number: 8895735Abstract: A preparation process of (6R)-tetrahydrobiopterin hydrochloride is provided, which comprises hydrogenating L-biopterin in the presence of a catalyst of Pt group metal in the basic substrate containing solvent, potassium hydroxide and potassium dihydrogen phosphate to obtain (6R)-tetrahydrobiopterin hydrochloride, wherein the pH value of the basic substrate is controlled by potassium hydroxide and potassium dihydrogen phosphate in the range of about 10 to about 13.Type: GrantFiled: November 15, 2010Date of Patent: November 25, 2014Assignee: Innopharmax, Inc.Inventors: Zhen Wang, Dongbing Zhao, Weida Wang, Jingbo Lan, Jinsong You
-
Patent number: 8883207Abstract: A controlled release carvedilol formulation for less frequent, preferably once daily administration is described. The controlled release formulation comprises a therapeutically effective amount of carvedilol or a pharmaceutically acceptable salt thereof, a matrix forming polymer, a solubility enhancer and a pharmaceutically acceptable carrier. In one embodiment, a controlled release formulation having a therapeutically effective amount of carvedilol is contained in two or more subunits having different release profiles. The controlled release formulation is usable in the treatment and/or prophylaxis of one or more conditions such as cardiovascular disorders.Type: GrantFiled: September 29, 2010Date of Patent: November 11, 2014Assignees: TSH Biopharm Corporation Ltd., Innopharmax, Inc.Inventors: Wei-Hua Hao, Tsung-Hsin Lin, Ta-Chien Lu
-
Publication number: 20140120166Abstract: A composition of entacapone comprising entacapone or pharmaceutically acceptable salts, PVPK30 and SDS is disclosed in the present invention, wherein the mass ratio of entacapone: PVPK30: SDS is 1:0.05-0.6:0.06-0.1. The present invention also discloses preparative method and use of the composition of entacapone.Type: ApplicationFiled: April 26, 2011Publication date: May 1, 2014Applicant: INNOPHARMAX, INC.Inventors: Wei-Hua Hao, Jong-Jing Wang, Hui-Yun Chen
-
Publication number: 20130197222Abstract: A preparation process of (6R)-tetrahydrobiopterin hydrochloride is provided, which comprises hydrogenating L-biopterin in the presence of a catalyst of Pt group metal in the basic substrate containing solvent, potassium hydroxide and potassium dihydrogen phosphate to obtain (6R)-tetrahydrobiopterin hydrochloride, wherein the pH value of the basic substrate is controlled by potassium hydroxide and potassium dihydrogen phosphate in the range of about 10 to about 13.Type: ApplicationFiled: November 15, 2010Publication date: August 1, 2013Applicant: INNOPHARMAX, INC.Inventors: Zhen Wang, Dongbing Zhao, Weida Wang, Jingbo Lan, Jingsong You
-
Publication number: 20120276198Abstract: A pharmaceutical composition used to treat Parkinson's disease contains levodopa, carbidopa and entacapone or pharmaceutically acceptable salt thereof, and at least one kind of pharmaceutically acceptable excipients. Entacapone is not mixed with levodopa or carbidopa in the pharmaceutical composition. The preparation method of the pharmaceutical composition includes making the first particles with levodopa and carbidopa, making the second particles with entacapone, and then pressing the two kinds of particles into tablets.Type: ApplicationFiled: December 25, 2009Publication date: November 1, 2012Applicant: INNOPHARMAX INC.Inventors: Weihua Hao, Jongjing Wang, Huiyun Chen
-
Publication number: 20120245212Abstract: A controlled release carvedilol formulation for less frequent, preferably once daily administration is described. The controlled release formulation comprises a therapeutically effective amount of carvedilol or a pharmaceutically acceptable salt thereof, a matrix forming polymer, a solubility enhancer and a pharmaceutically acceptable carrier. In one embodiment, a controlled release formulation having a therapeutically effective amount of carvedilol is contained in two or more subunits having different release profiles. The controlled release formulation is usable in the treatment and/or prophylaxis of one or more conditions such as cardiovascular disorders.Type: ApplicationFiled: September 29, 2010Publication date: September 27, 2012Applicants: INNOPHARMAX, INC., TSH BIOPHARM CORPORATION LTD.Inventors: Wei-Hua Hao, Tsung-Hsin Lin, Ta-Chien Lu
-
Publication number: 20100273730Abstract: The present invention provides an oral self micro-emulsifying pharmaceutical composition of a hydrophilic drug or a pharmaceutically acceptable salt thereof which, in addition to the hydrophilic drug, one or more solvents for solving the hydrophilic drug to form a drug-solvent solution and a surfactant system, further comprises one or more hydrophilic carrier which are compatible with said drug-solvent solution and the surfactant system. The oral self micro-emulsifying pharmaceutical composition of the invention exhibits comparative bioavailability to that of the hydrophilic drug through injection and is stable during storage. A method for preparing the oral self micro-emulsifying pharmaceutical composition is also provided.Type: ApplicationFiled: April 26, 2010Publication date: October 28, 2010Applicant: INNOPHARMAX, INC.Inventors: Chang-Shan Hsu, Wei-Hua Hao, Jong-Jing Wang, Tsung-Hsin Lin
-
Publication number: 20090130198Abstract: The invention pertains to a self-emulsifying pharmaceutical composition containing a lipophilic drug, a surfactant, and a hydrophilic carrier. The invention also provides a method for making the pharmaceutical composition for increasing the bioavailability of a drug by self-emulsification.Type: ApplicationFiled: November 21, 2007Publication date: May 21, 2009Applicant: INNOPHARMAX INC.Inventors: Wei-Hua Hao, Jong-Jing Wang, Chang-Shan Hsu